BioLineRx has received FDA approval for its drug APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to assist in mobilising haematopoietic stem cells for peripheral blood collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA is administered through subcutaneous injection.
The approval of APHEXDA addresses the significant need for new therapies to provide more reliable stem cell mobilisation compared to using filgrastim alone. It offers the advantage of fewer days of aphaeresis sessions and reduces the number of filgrastim doses required for individuals living with multiple myeloma.
The FDA approval of APHEXDA is based on the promising results from the 2-part, Phase 3 GENESIS trial. This trial was a randomised, double-blind, placebo-controlled study that assessed the safety and efficacy of APHEXDA (motixafortide) in combination with filgrastim versus a placebo combined with filgrastim for the mobilisation of haematopoietic stem cells in multiple myeloma patients.
The strong efficacy data obtained from the GENESIS trial, which included patients representative of the current multiple myeloma population, suggests that APHEXDA will play a critical role in meeting unmet needs and potentially introduce a new treatment approach for this challenging cancer.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!